Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Magenta Therapeutics Inc
(NQ:
MGTA
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Sep 11, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Magenta Therapeutics Inc
MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA
August 07, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Cvent Holding Corp. (Nasdaq - CVT), Absolute Software Corporation (Nasdaq – ABST), Home Point Capital, Inc. (Nasdaq – HMPT), Magenta Therapeutics, Inc. (Nasdaq –
May 11, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA
May 03, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ruth’s Inc. (Nasdaq – RUTH), Magenta Therapeutics, Inc. (Nasdaq – MGTA), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX)
May 03, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
MGTA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Magenta Therapeutics, Inc. Is Fair to Shareholders
May 03, 2023
From
Halper Sadeh LLC
Via
Business Wire
Magenta Therapeutics Reports First Quarter Financial Results, Early Clinical Observations from MGTA-117 Clinical Trial and Other Program Highlights
May 16, 2022
From
Magenta Therapeutics
Via
Business Wire
InvestorNewsBreaks – Magenta Therapeutics Inc. (NASDAQ: MGTA) Featured in Mizuho Securities Research Report
April 18, 2022
Via
Investor Brand Network
Magenta Therapeutics Focuses R&D and Operational Spending, Reduces Workforce and Extends Cash Runway
April 14, 2022
From
Magenta Therapeutics
Via
Business Wire
Magenta Therapeutics Highlights Recent Pipeline Progress and Milestone Expectations for 2022
January 10, 2022
From
Magenta Therapeutics
Via
Business Wire
Magenta Therapeutics to Present at the J.P. Morgan Healthcare Conference and the B. Riley Virtual Oncology Conference
January 05, 2022
From
Magenta Therapeutics
Via
Business Wire
Magenta Therapeutics Highlights Presentations of Data Related to Stem Cell Mobilization and Targeted Conditioning at the 2021 American Society of Hematology (ASH) Annual Meeting
December 14, 2021
From
Magenta Therapeutics
Via
Business Wire
Magenta Therapeutics Reports Third Quarter Financial Results and Program Highlights
November 04, 2021
From
Magenta Therapeutics, Inc.
Via
Business Wire
Magenta Therapeutics Announces Data Presentations Related to its Mobilization and Conditioning Programs at the 2021 American Society of Hematology (ASH) Annual Meeting
November 04, 2021
From
Magenta Therapeutics
Via
Business Wire
Magenta Therapeutics Appoints Jeffrey Humphrey, M.D. as Chief Medical Officer
October 04, 2021
From
Magenta Therapeutics, Inc.
Via
Business Wire
Magenta Therapeutics to Participate in 2021 Cantor Virtual Global Healthcare Conference
September 21, 2021
From
Magenta Therapeutics, Inc.
Via
Business Wire
Magenta Therapeutics Announces IND Clearance for MGTA-117 Targeted Conditioning Clinical Trial
September 15, 2021
From
Magenta Therapeutics, Inc.
Via
Business Wire
Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights
August 05, 2021
From
Magenta Therapeutics, Inc.
Via
Business Wire
Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in August
August 03, 2021
From
Magenta Therapeutics, Inc.
Via
Business Wire
Magenta Therapeutics Announces Update on U.S. FDA Investigational New Drug Application for MGTA-117 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome
July 21, 2021
From
Magenta Therapeutics, Inc.
Via
Business Wire
Magenta Therapeutics Appoints Caren Deardorf as Chief Commercial Officer
July 06, 2021
From
Magenta Therapeutics, Inc.
Via
Business Wire
Magenta Therapeutics Appoints Thomas Beetham as Chief Legal Officer
June 14, 2021
From
Magenta Therapeutics
Via
Business Wire
Magenta Therapeutics Announces Additional Preliminary Positive Results from Ongoing Phase 2 Clinical Trial of MGTA-145 and Plerixafor in Patients with Multiple Myeloma at the American Society of Clinical Oncology (ASCO) Annual Meeting
June 04, 2021
From
Magenta Therapeutics
Via
Business Wire
Magenta Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
June 03, 2021
From
Magenta Therapeutics
Via
Business Wire
Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in May
May 14, 2021
From
Magenta Therapeutics
Via
Business Wire
Magenta Therapeutics Announces Positive Preliminary Results from Phase 2 Clinical Trial of MGTA-145 in Multiple Myeloma and Provides an Update on its Anticipated Clinical Study with MGTA-117
May 12, 2021
From
Magenta Therapeutics
Via
Business Wire
Magenta Therapeutics Announces $86.4 Million Common Stock Investment from Multiple Investors
May 12, 2021
From
Magenta Therapeutics, Inc.
Via
Business Wire
Magenta Therapeutics Reports First Quarter Financial Results and Recent Program Highlights
May 06, 2021
From
Magenta Therapeutics
Via
Business Wire
Magenta Therapeutics Appoints David Nichols as Chief Technical Officer
April 19, 2021
From
Magenta Therapeutics
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.